**Agenda EPEN summer meeting – 8 June 2023**

**Girton College, Cambridge CB3 0JG**

**Chairs**: Arun Saraswatula (morning), Eme Nugent-Cruse (afternoon)

09:45 – 10:00 **Coffee/tea Welcome**

10:00 – 10:45 Action Log

Terms of Reference- EPEN

Epilepsy 12 - Epilepsy Information Standard

Regional projects - Rett syndrome – *Asma Soltani/ Lipi Shekhar*

AOB

10:50 – 11:20 Case series of treatment responses in Dravet syndrome – *Nik Cholidis*

11:25 – 11:45 Epilepsy training take up in schools - *Louise Bonnor-Moris/ J Hill/ Katie Burton*

11:50 – 12:05 Case (?Jacob Shipman)

12:10 - 12:25 New regional paediatric multiple sclerosis study – *J Holland*

12:30 - 13:30 **Lunch**

13:30 – 13:55 Can children with epilepsy be converted from liquid to tablet formulations and what would the cost savings be? – *Emma Mason/ Kate Riley*

14:00 - 14:25 Behaviour assessment services - *Andrew Paterson* *(NCYPE)*

14:30 - 15:00 **Photo and break**

15:00 - 15:15 Effective use of Dexmed sedation in children – *Helen Lin Jia Qi /A Parker*

15:20 – 15:50 V-create and Video-telemetry – *R Thornton/A Michell*

15:55 - 16:10 Case (Michail Sergentanis/Gautam)

16:15 - 16:30 Case (tbc)

16:30 **Closing**

**Information about our sponsors (overleaf)**

**Eisai** to be confirmed

**Ethypharm** is an independent pharmaceutical company with global reach. It is dedicated to developing innovative drugs, primarily for the treatment of pain, addiction and critical care. Ethypharm has unique experience of more than 30 years in developing its own portfolio of drugs based on state-of–the-art proprietary technologies. Ethypharm also develop complex generics that contribute towards optimisation of healthcare costs providing meaningful cost savings to CCG’s and Health Boards without compromising on healthcare delivery for patients. For further information on Ethypharm UK or any of our medicines please contact us; telephone 01628 551900 or via email

**Jazz Pharmaceuticals** Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases- often with limited or no therapeutic options. Following the acquisition of GW pharmaceuticals, together we are continuing our commitment to patients and pursuing innovative and differential therapies that establish new or better standards of care in neuroscience and oncology. Job code: UK-JPC-2300002. Date of preparation: Jan 2023

**LivaNova PLC** is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com

**Proveca Ltd** is a UK based pharmaceutical company specialising in the development and licensing of off-patent medicines for children throughout Europe www.proveca.co.uk. Marketing approval (product licence) is gained via a Paediatric Use Marketing Authorisation (PUMA), a regulatory route developed specifically for licensing off-patent medicines for children in Europe. Proveca’s first PUMA (Sialanar) was granted in September 2016. Please see website for more information <https://www.sialanar.co.uk/prescribing-information/>.

**UCB** is a global biopharmaceutical company dedicated to discovering and developing treatments that aim to transform the lives of people living with neurological and immunological conditions. Because there is no such thing as an ‘average patient’ we use the tools, channels and scientific advances at our disposal to develop a deep understanding of a disease and the real needs of patients. Working in collaboration with leading researchers from academia, medical charities and industry we strive to deliver cutting-edge science, innovative drugs and practical solutions patients need to improve their quality of life. We are inspired by patients. Driven by science. [www.ucbpharma.co.uk](http://www.ucbpharma.co.uk)

**Veriton Pharma Ltd.** (formerly Special Products Ltd.) was founded in 1997 by a pharmacist with substantial experience in the formulation of medicines gained while working at major pharmaceutical companies and within the NHS.

Veriton focuses on the development and manufacturing of licensed medicines, and unlicensed medicines for patients with special requirements that licensed products cannot meet, notably in the fields of epilepsy, neurology, and rare paediatric conditions such as inborn errors of metabolism (IEMs). In May 2020 Veriton Pharma were acquired by SERB Speicality Pharmaceuticals, who further acquired BTG Speciality Pharmaceuticals in March 2021 to form the SERB Pharmaceuticals group.

**Zogenix** is committed to developing and commercializing transformative therapies for people living with rare diseases that can dramatically improve the lives of patients and their families.